|Audit||Nominating and Governance||Compensation|
|Axel Bolte, M.B.A.|
Investment Advisor, HBM Healthcare Investments AG
Axel Bolte, M.B.A., serves as an Investment Advisor of the Private Equity Team at HBM Partners Ltd. and HBM BioVentures AG, based in Zurich, Switzerland. He has nine years' experience in healthcare venture capital. Mr. Bolte previously worked as an investment manager for Swiss venture capital company NMT New Medical Technologies AG, as well as a scientist at Serono SA, where he held a position in R&D management.
He currently serves or has served on the board of directors of several biotechnology companies, including Newron Pharmaceuticals SpA, Nabriva Therapeutics AG, PTC Therapeutics, Inc., MPex Pharmaceuticals, Inc., Lux Biosciences, Inc. and Kolltan Pharmaceuticals, Inc.
Mr. Bolte received a Master of Business Administration (M.B.A.) degree from the University of St. Gallen, Switzerland and a degree in biochemistry from the Swiss Federal Institute of Technology in Zurich, Switzerland.
|Thomas Dyrberg, M.D., Ph.D.|
Senior Partner, Novo Ventures and Novo A/S
Thomas Dyrberg, M.D., Ph.D. serves as a Senior Partner of Novo Ventures and Novo A/S. He previously held research positions at the Hagedorn Research Institute in Gentofte, Denmark and at the Scripps Research Institute in La Jolla, Calif., and has published several articles within the fields of diabetes, immunology and autoimmunity. Dr. Dyrberg has also worked for Novo Nordisk A/S in health care discovery and clinical drug development as an International Clinical Project Manager.
He currently serves or has served on the board of directors of several biotechnology companies, including Veloxis Pharmaceuticals A/S, Gloucester Pharmaceuticals, Inc., Rejuvenon Corp., Allocure Inc., Veloxis, Lux Biosciences, Inc., Sapphire Therapeutics Inc., Delenex Therapeutics AG, BioMimetic Therapeutics, Inc. and Helsinn Therapeutics (U.S.), Inc.
Dr. Dyrberg received his M.D. degree from the University of Copenhagen in 1981 and his Doctor of Medical Science (D.M.Sc.) degree, also from the University of Copenhagen, in 1986.
|Mike Ross, Ph.D.|
Managing Partner, SV Life Sciences
Michael Ross, Ph.D. serves as a Managing Partner of SV Life Sciences (SVLS). He was the tenth employee at Genentech, where he worked for 13 years in various roles including team leader and Vice President of Development. Dr. Ross also started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell) and was also Managing Partner at Didyma, LLC, a biotechnology management consulting firm.
Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the faculty of Thayer School of Engineering at Dartmouth College.
Dr. Ross received his Bachelor of Arts (A.B.) from Dartmouth College, his Doctor of Philosophy (Ph.D.) degree in Chemistry from the California Institute of Technology (Caltech), and completed a Post-Doctorate program in Molecular Biology at Harvard University.
Former Partner, Wilmer Cutler Pickering Hale and Dorr LLP